MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202641049660 A) filed by Anurag University, Hyderabad, Telangana, on April 18, for 'antidiabetic and anti-cataract potential of cressa cretica ethanolic extract in stz-induced experimental diabetes.'
Inventor(s) include Dr Naveen Pathakala; Dr Rahul Kshirsagar; Dr Mohammed Sayeed; Dr D. Krishna Prasad; Dr Vasudha Bakshi; and M. Divya.
The application for the patent was published on May 1, under issue no. 18/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a pharmaceutical composition comprising an ethanolic extract of Cressa cretica (CCEE) for the management of diabetic cataract and associated metabolic disorders. The composition includes bioactive phytoconstituents obtained through Soxhlet extraction and optionally formulated with pharmaceutically acceptable carriers. The invention demonstrates dose-dependent therapeutic efficacy in streptozotocin-induced diabetic cataract models at 200-400 mg/kg body weight. The extract exhibits significant antihyperglycemic, antioxidant, and antihyperlipidemic activities by reducing blood glucose levels, improving lipid profile, and enhancing endogenous antioxidant enzymes such as SOD, catalase, and GST while reducing malondialdehyde levels. It further inhibits aldose reductase activity and sorbitol accumulation in the polyol pathway, thereby preventing lens opacity. Additionally, the composition restores lens protein integrity and delays cataract progression. Overall, the invention provides a safe, plant-based multi-target therapeutic approach for the prevention and treatment of diabetic cataract and related metabolic complications."
Disclaimer: Curated by HT Syndication.
